Small Cell Lung Cancer Articles Published in 2020 and 2021

Overcoming Chemotherapy Resistance in SCLC by Herzog, Brett H. et al.  
Journal of Thoracic Oncology, in press

Molecular Subtypes of Primary SCLC Tumors and Their Associations With Neuroendocrine and Therapeutic Markers by Qu, Song et al.  
Journal of Thoracic Oncology, in press

Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study by Blackhall, Fiona et al.  
Journal of Thoracic Oncology, Volume 16, Issue 9, 1547 – 1558

A Phase 1–2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC by Malhotra, Jyoti et al.  
Journal of Thoracic Oncology, Volume 16, Issue 9, 1559 – 1569

Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage SCLC: Results From the Phase 3 MERU Study by Johnson, Fiona L. et al.  
Journal of Thoracic Oncology, Volume 16, Issue 9, 1570 – 1581

Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study by Ai, Xinghao et al.  
Journal of Thoracic Oncology, Volume 16, Issue 8, 1403 – 1414

Beyond Programmed Death-Ligand 1: B7-H6 Emerges as a Potential Immunotherapy Target in SCLC by Thomas, Portia L. et al.  
Journal of Thoracic Oncology, Volume 16, Issue 7, 1211 – 1223

YAP1 Expression in SCLC Defines a Distinct Subtype With T-cell–Inflamed Phenotype by Owonikoko, Taofeek K. et al.  

Camrelizumab Plus Apatinib in Extensive-Stage SCLC (PASSION): A Multicenter, Two-Stage, Phase 2 Trial by Fan, Yun et al.  

Journal of Thoracic Oncology, Volume 16, Issue 1, 66 – 75

SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization by Baine, Marina K et al. Journal of Thoracic Oncology, Volume 15, Issue 12, 1823 – 1835

Role of mTOR As an Essential Kinase in SCLC by Kern, Jeffrey A. et al. Journal of Thoracic Oncology, Volume 15, Issue 9, 1522 – 1534


New Approaches to SCLC Therapy: From the Laboratory to the Clinic by Poirier, John T. et al. Journal of Thoracic Oncology, Volume 15, Issue 4, 520 – 540
Small Cell Lung Cancer Articles Published in 2020 and 2021

SCLC, Paraneoplastic Dermatomyositis, Positive Transcription Intermediary Factor 1-γ, and Point Mutation in the Transcription Intermediary Factor 1-γ Coding Gene: A Case Report by Arnon, Johnathan et al. JTO Clinical and Research Reports, Volume 2, Issue 9, 100217

Pembrolizumab Plus Amrubicin in Patients With Relapsed SCLC: Multi-Institutional, Single-Arm Phase 2 Study by Akamatsu, Hiroaki et al. JTO Clinical and Research Reports, Volume 2, Issue 7, 100184

Salvage Surgery for Patients With Local Recurrence or Persistent Disease After Treatment With Chemoradiotherapy for SCLC by Joosten, Pieter J.M. et al. JTO Clinical and Research Reports, Volume 2, Issue 5, 100172

Genomic and Transcriptomic Characterization of Relapsed SCLC Through Rapid Research Autopsy by Chen, Hui-Zi et al. JTO Clinical and Research Reports, Volume 2, Issue 4, 100164

Current Landscape of Immunotherapy Trials Involving the Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Axis in Intrathoracic Tumors by Kareff, Samuel A. et al. JTO Clinical and Research Reports, Volume 2, Issue 4, 100149

Circulating Tumor DNA as a Biomarker of Radiographic Tumor Burden in SCLC by Smith, Jarrod T. et al. JTO Clinical and Research Reports, Volume 2, Issue 3, 100110

Racial and Other Healthcare Disparities in Patients With Extensive-Stage SCLC by Tapan, Umit et al. JTO Clinical and Research Reports, Volume 2, Issue 1, 100109

Successful Treatment of EGFR-Mutant Synchronous SCLC and Lung Adenocarcinoma With Osimertinib by Batra, Ullas et al. JTO Clinical and Research Reports, Volume 2, Issue 1, 100098

Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC by Ricciuti, Biagio et al. JTO Clinical and Research Reports, Volume 1, Issue 4, 100074
Blood-Based Surveillance Monitoring of Circulating Tumor DNA From Patients With SCLC Detects Disease Relapse and Predicts Death in Patients With Limited-Stage Disease by Iams, Wade T. et al. JTO Clinical and Research Reports, Volume 1, Issue 2, 100024

Development and Validation of a Simplified Prognostic Score in SCLC by Negre, Elodie et al. JTO Clinical and Research Reports, Volume 1, Issue 1, 100016

For more information, contact journals@iaslc.org